Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190555 | 1.00 | — | — | |
| SCHEMBL21089261 | 0.93 | JAK1 (0.36) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL6977767 | 0.90 | — | — | |
| SCHEMBL2751529 | 0.90 | SMN1; SMN2 (0.39) | JAK1JAK2DPP4SMN1; SMN2DPP8 | |
| SCHEMBL21781847 | 0.89 | JAK1 (0.38) | JAK1JAK2TYK2JAK3DPP4 | |
| SCHEMBL21782065 | 0.89 | ALDH1A1 (0.38) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL9342162 | 0.89 | JAK1 (0.35) | JAK1JAK2TYK2JAK3DPP4 | |
| SCHEMBL15014481 | 0.89 | ALDH1A1 (0.38) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL3167403 | 0.88 | DPP4 (0.40) | ALDH1A1DPP4SMN1; SMN2DPP8DPP9 | |
| SCHEMBL6160369 | 0.88 | DPP4 (0.40) | ALDH1A1DPP4SMN1; SMN2DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | claimed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | claimed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | claimed |
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | disclosed |
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | disclosed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | disclosed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | disclosed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | disclosed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | NAAA, ADH1A, ADH1C | JAK1 4558/4885JAK2 4767/4885TYK2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.